NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Supreme Court Of India
    Central Bureau Of Investigation (CBI)
    Indian Army
    Indian Railways
    Indian Air Force
    NewsBytes
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / Glenmark launches COVID-19 drug FabiFlu at Rs. 103 per tablet
    India

    Glenmark launches COVID-19 drug FabiFlu at Rs. 103 per tablet

    Glenmark launches COVID-19 drug FabiFlu at Rs. 103 per tablet
    Written by Siddhant Pandey
    Jun 20, 2020, 11:08 pm 3 min read
    Glenmark launches COVID-19 drug FabiFlu at Rs. 103 per tablet

    Glenmark Pharmaceuticals Ltd. launched the antiviral drug favipiravir on Saturday for the treatment of mild to moderate cases of COVID-19. The Mumbai-based firm had received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) on Friday. The drug will reportedly be sold under the brand name FabiFlu at a price of Rs. 103 per tablet by June-end. Here are more details.

    What is favipiravir?

    Favipiravir is an antiviral medication that has been in use in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections. The drug has shown clinical improvement of up to 88% in mild to moderate COVID-19 cases. It can be used for COVID-19 patients with co-morbid conditions such as diabetes and heart disease, Glenmark said.

    FabiFlu will be launched commercially next week

    FabiFlu is the first oral favipiravir-approved medication in India. It will be launched commercially next week and will likely be available across chemist outlets on a prescription basis by the end of June, The Print reported. The drug will be sold in a strip of 34 oral tablets of 200 mg each at a maximum retail price of Rs. 3,500 (Rs. 103 per tablet).

    What is the recommended dose for the drug?

    Glenmark said the recommended dose for FabiFlu is 1,800 mg twice daily on day one, and 800 mg twice daily subsequently up to day 14. The drug—being produced by Glenmark at its Baddi facility in Himachal Pradesh—will be available through both hospitals and retail.

    'Approval for FabiFlu comes as COVID-19 cases spiral in India'

    Glenmark Pharmaceuticals Chairman and MD Glenn Saldanha said in a statement, "This approval comes at a time when cases in India are spiraling like never before, putting tremendous pressure on our healthcare system." Till Saturday morning, India had reported 3,95,048 COVID-19 cases, after witnessing a record spike of 14,516 cases. The total tally includes 1,68,269 active cases, 2,13,830 recoveries, and 12,948 deaths.

    Glenmark to work with government to make FabiFlu quickly accessible

    Saldanha said, "Glenmark will work closely with the government and medical community to make FabiFlu quickly accessible to patients across the country." Glenmark hopes that the availability of effective treatment will help reduce the pressure on the healthcare system, Saldanha said.

    Approval granted as part of accelerated process

    The Drugs Controller General of India (DCGI) had granted manufacturing and marketing approval for FabiFlu to Glenmark on Friday. The approval was granted as part of an accelerated approval process considering the coronavirus crisis in India. The approval's restricted use involves responsible medication usage wherein every patient is required to have signed informed consent before treatment initiation, Glenmark said.

    'Favipiravir has wide therapeutic safety margin for COVID-19'

    Sujesh Vasudevan—President India Formulations, Middle East and Africa, Glenmark Pharmaceuticals—said, "We chose to initiate work on favipiravir, as it has proven in-vitro activity against SARS-CoV-2 virus, which is the virus responsible for COVID-19." Vasudevan said, "Second is it has a wide therapeutic safety margin for COVID-19 at the dose that we administer," adding that FabiFlu has a huge benefit as an oral product.

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Latest
    Himachal Pradesh
    Africa
    Drugs Controller General of India
    Coronavirus

    Latest

    Xiaomi's RedmiBook Pro is now cheaper on Flipkart: Check offers Xiaomi
    3rd straight draw for Bayern in Bundesliga 2022-23: Key stats Bundesliga
    Odisha Health Minister Naba Das shot by police officer; critical Odisha
    Donald Trump kicks off 2024 US presidential election bid Donald Trump

    Himachal Pradesh

    Mercury rises in Delhi, heavy snowfall likely in J&K, Himachal Cold Wave
    Himachal Pradesh: Sukhvinder Sukhu government reinstates Old Pension Scheme Congress Party
    Himachal Pradesh: 7 ministers take oath in first cabinet expansion  Congress Party
    5 top destinations in India for adventure sports Travel And Tourism

    Africa

    Uganda: Hippo swallows 2-year-old kid before spitting him out alive Uganda
    Nigeria: Armed men kill 12 in mosque, abduct several others Nigeria
    Tanzania: Passenger plane crashes into Lake Victoria, rescue operations underway Tanzania
    Gurugram to get the world's largest safari park Gurugram

    Drugs Controller General of India

    Serum Institute seeks DCGI's approval for Covovax as booster dose Serum Institute of India
    Lumpy skin disease kills 67,000 cattle across India: Details here Narendra Modi
    Clinical trials for nasal COVID-19 vaccine complete: Bharat Biotech Paris
    DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years COVID-19 Vaccine

    Coronavirus

    COVID-19 outbreak has infected 80% of Chinese population China
    COVID-19: WHO urges travelers to mask up amid XBB.1.5 spread World Health Organization
    China: Hospitals cancel New Year holidays to meet patients' requirements China
    #NewsBytesExplainer: What's XBB.1.5, COVID-19 sub-variant triggering cases spike in US  COVID-19

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023